Keywords: strong, ph, iii, data, j/basilea, ceftobiprole, health
Strong Ph III data for J&J/Basilea's ceftobiprole
Article | 15 October 2007
US health care major Johnson & Johnson's investigational antibiotic ceftobiprole was found to clinically cure 86% of patients with diabetic foot infections ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
